177 related articles for article (PubMed ID: 33349457)
21. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
22. Design and identification of two novel resveratrol derivatives as potential LSD1 inhibitors.
Xu Y; Gao Y; Yang M; Wang M; Lu J; Wu Z; Zhao J; Yu Y; Wang C; Zhao Z; Gao Q; Duan Y; Han D
Future Med Chem; 2021 Sep; 13(17):1415-1433. PubMed ID: 34232085
[No Abstract] [Full Text] [Related]
23. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
[TBL] [Abstract][Full Text] [Related]
24. Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia.
Li Y; Sun Y; Zhou Y; Li X; Zhang H; Zhang G
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):207-217. PubMed ID: 33307878
[TBL] [Abstract][Full Text] [Related]
25. Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
Ren C; Lin Y; Liu X; Yan D; Xu X; Zhu D; Kong L; Han C
Bioorg Chem; 2021 Mar; 108():104666. PubMed ID: 33550070
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
[TBL] [Abstract][Full Text] [Related]
27. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
Song Y; Zhang H; Yang X; Shi Y; Yu B
Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
[TBL] [Abstract][Full Text] [Related]
28. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
29. Salinomycin suppresses cancer cell stemness and attenuates TGF-β-induced epithelial-mesenchymal transition of renal cell carcinoma cells.
Liu L; Wang Q; Mao J; Qin T; Sun Y; Yang J; Han Y; Li L; Li Q
Chem Biol Interact; 2018 Dec; 296():145-153. PubMed ID: 30273566
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel indole derivatives as highly potent and efficacious LSD1 inhibitors.
Zhang X; Sun Y; Huang H; Wang X; Wu T; Yin W; Li X; Wang L; Gu Y; Zhao D; Cheng M
Eur J Med Chem; 2022 Sep; 239():114523. PubMed ID: 35732082
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.
Selka A; Doiron JA; Lyons P; Dastous S; Chiasson A; Cormier M; Turcotte S; Surette ME; Touaibia M
Eur J Med Chem; 2019 Oct; 179():347-357. PubMed ID: 31260889
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A
ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576
[TBL] [Abstract][Full Text] [Related]
34. Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy.
Chen D; Sun X; Zhang X; Cao J
J Biochem Mol Toxicol; 2018 Sep; 32(9):e22195. PubMed ID: 30004155
[TBL] [Abstract][Full Text] [Related]
35. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
36. 4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.
He X; Gao Y; Hui Z; Shen G; Wang S; Xie T; Ye XY
Bioorg Med Chem Lett; 2020 May; 30(10):127109. PubMed ID: 32201021
[TBL] [Abstract][Full Text] [Related]
37. Baicalin, a natural LSD1 inhibitor.
Zheng YC; Shen DD; Ren M; Liu XQ; Wang ZR; Liu Y; Zhang QN; Zhao LJ; Zhao LJ; Ma JL; Yu B; Liu HM
Bioorg Chem; 2016 Dec; 69():129-131. PubMed ID: 27814566
[TBL] [Abstract][Full Text] [Related]
38. Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors.
Liu HM; Suo FZ; Li XB; You YH; Lv CT; Zheng CX; Zhang GC; Liu YJ; Kang WT; Zheng YC; Xu HW
Eur J Med Chem; 2019 Aug; 175():357-372. PubMed ID: 31096156
[TBL] [Abstract][Full Text] [Related]
39. LPE-1, an orally active pyrimidine derivative, inhibits growth and mobility of human esophageal cancers by targeting LSD1.
Wang B; Zhao B; Pang LP; Zhao YD; Guo Q; Wang JW; Zheng YC; Zhang XH; Liu Y; Liu GY; Guo WG; Wang C; Li ZH; Mao XJ; Yu B; Ma LY; Liu HM
Pharmacol Res; 2017 Aug; 122():66-77. PubMed ID: 28571892
[TBL] [Abstract][Full Text] [Related]
40. Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen.
Ota Y; Itoh Y; Kaise A; Ohta K; Endo Y; Masuda M; Sowa Y; Sakai T; Suzuki T
Angew Chem Int Ed Engl; 2016 Dec; 55(52):16115-16118. PubMed ID: 27882656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
